The SLC28A2 antibody is a research tool designed to detect and study the solute carrier family 28 member 2 (SLC28A2), a protein encoded by the SLC28A2 gene in humans. SLC28A2. also known as concentrative nucleoside transporter 2 (CNT2), is a membrane-bound transporter protein that facilitates the sodium-dependent uptake of purine nucleosides (e.g., adenosine, guanosine) and some pyrimidine analogs, playing a critical role in nucleoside homeostasis, drug absorption, and cellular metabolism. It is predominantly expressed in epithelial tissues, including the intestine, liver, and kidney, as well as in immune cells. Antibodies targeting SLC28A2 are typically developed in hosts such as rabbits or mice using immunogenic peptide sequences or recombinant protein fragments. These antibodies are widely utilized in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to investigate the protein’s expression, localization, and function in physiological and pathological contexts. Research involving SLC28A2 antibodies has contributed to understanding its role in drug pharmacokinetics (e.g., anticancer nucleoside analogs), genetic disorders linked to nucleoside transport deficiencies, and metabolic diseases. Validations often include knockout controls or siRNA-based silencing to confirm specificity. Such studies highlight its potential as a therapeutic target or biomarker in cancer, immune regulation, and metabolic syndromes.